Home > Insider Trading > Filing (0000899243-21-044916)

Filing Details

Accession Number:: 0000899243-21-044916
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-11-16 19:57:50
Reporting Period:: 2021-11-12

Accepted Time:: 2021-11-16 19:57:50
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1640455	Jounce Therapeutics Inc.	JNCE	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1180428	J Mark Levin	C/O Third Rock Ventures, Llc, 29 Newbury Street, 3Rd Floor Boston MA 02116	No	No	Yes	No
1192595	I Robert Tepper	29 Newbury Street, 3Rd Floor Boston MA 02116	No	No	Yes	No
1192603	P Kevin Starr	29 Newbury Street, 3Rd Floor Boston MA 02116	No	No	Yes	No
1569705	Third Rock Ventures Iii, L.p.	C/O Third Rock Ventures, Llc, 29 Newbury Street, 3Rd Floor Boston MA 02116	No	No	Yes	No
1637299	Trv Gp Iii, Llc	29 Newbury Street, 3Rd Floor Boston MA 02116	No	No	Yes	No
1637300	Third Rock Ventures Gp Iii, L.p.	29 Newbury Street, 3Rd Floor Boston MA 02116	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2021-11-12	1,900,000	$8.38	1,148,780	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	2,697,829	Indirect	See footnote
Common Stock	284,344	Indirect	See footnote
Common Stock	283,850	Indirect	See footnote
Common Stock	283,858	Indirect	See footnote

Footnotes

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.30 to $8.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.
These shares are directly held by Third Rock Ventures II, L.P. ("TRV II"). The general partner of TRV II is Third Rock Ventures GP II, L.P. ("TRV GP II"). The general partner of TRV GP II is TRV GP II, LLC ("TRV GP II LLC"). The individual managers of TRV GP II LLC are Levin, Starr and Tepper. Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.
The shares are directly held by Levin.
The shares are directly held by Starr.
The shares are directly held by Tepper.